相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Sacha Gnjatic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Aaron S. Mansfield et al.
CLINICAL CANCER RESEARCH (2016)
Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
Rachel E. Sanborn et al.
CANCER RESEARCH (2016)
CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
Tomasz Ahrends et al.
CANCER RESEARCH (2016)
Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
A. Murtaza et al.
EUROPEAN JOURNAL OF CANCER (2016)
Rationale for anti-OX40 cancer immunotherapy
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multispectral Imaging of T and B Cells in Murine Spleen and Tumor
Zipei Feng et al.
JOURNAL OF IMMUNOLOGY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Multiplexed tissue biomarker imaging
Edward C. Stack et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Combination Approaches with immune-Checkpoint Blockade in Cancer Therapy
Maarten Swart et al.
FRONTIERS IN ONCOLOGY (2016)
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells
Chandra Sekhar Boddupalli et al.
JCI INSIGHT (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Venky Ramakrishna et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma
Zipei Feng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
Edward C. Stack et al.
METHODS (2014)
When Tissue Antigens and Antibodies Get Along: Revisiting the Technical Aspects of Immunohistochemistry-The Red, Brown, and Blue Technique
J. A. Ramos-Vara et al.
VETERINARY PATHOLOGY (2014)
A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays
Wei Huang et al.
HUMAN PATHOLOGY (2013)
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Zhiqiang Guo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor
Michael J. Gough et al.
CANCER RESEARCH (2008)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Silvia Piconese et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Multiple immunoenzyme staining: Methods and visualizations for the observation with spectral imaging
Chris M. van der Loos
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2008)
Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: From experiments to hypothesis
Shan-Rong Shi et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2007)
AgarCyto: A novel cell-processing method for multiple molecular diagnostic analyses of the uterine cervix
HMJ Kerstens et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2000)
Engagement of the OX-40 receptor in vivo enhances antitumor immunity
AD Weinberg et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
